Korea FDA Targets 30 Firms For Offering Rebates; Orders 21 Drugs Off The Market For 30 Days
This article was originally published in PharmAsia News
Executive Summary
KFDA has imposed fines and ordered some drugs off the market for 30 days as penalties to pharma companies involved in rebates; more such actions are planned.
You may also be interested in...
Korea's Antitrust Watchdog Says Rebates Continuing Despite New Law; Levies $11 Million In Fines
SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.